Epigenomics AG

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool provides set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of colorectal and lung cancers. In addition, the company engages in the research and identification of additional DNA methylation biomarkers for prostate, bladder, breast, and ovarian cancers. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.